exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087997 RNA Name: hsa-miR-29c-3p RNA Type: miRNA Chromosome: chr1 Starnd: - Coordinate: Start Site(bp): 207801865 End Site(bp): 207801886 External Links: hsa-miR-29c-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AMER1 chrX 64185117 64205708 - APH1A chr1 150265399 150269580 - APP chr21 25880550 26171128 - BCL11A chr2 60450520 60554467 - BIRC5 chr17 78214186 78225636 + C1QTNF6 chr22 37180166 37199385 - CALU chr7 128739292 128773400 + CREG1 chr1 167529117 167553805 - FASN chr17 82078338 82098294 - FBXO10 chr9 37510892 37576380 - GATAD2B chr1 153789030 153923360 - KLHDC3 chr6 43014103 43021298 + KLHL28 chr14 44924319 45042322 - KMT5C chr19 55339853 55348121 + NASP chr1 45583846 45618904 + NMI chr2 151270470 151289894 - PER3 chr1 7784320 7845177 + RNF138 chr18 32091874 32131561 + SH3GLB1 chr1 86704570 86748184 + SP1 chr12 53380176 53416446 + CTSS chr1 150730188 150765792 - KDM5B chr1 202724495 202808487 - NREP chr5 111662621 111997464 - RINT1 chr7 105532169 105567677 + RPL13 chr16 89560657 89566828 + ZNF318 chr6 43307134 43369647 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000018 chr1 15860731 15863309 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC007036.3 chr7 30157531 30159534 + AC012146.1 chr17 5111468 5115004 + AC018521.1 chr17 47945424 47981736 + AL137129.1 chr14 61734138 61776260 + AL355488.1 chr1 110370154 110373003 + AL391244.1 chr1 1420245 1422691 + AP001432.1 chr21 37221419 37237744 + H19 chr11 1995176 2001470 - MIR4458HG chr5 8450701 8486930 + MIR497HG chr17 7015818 7019659 - MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.